Larvol Delta - VIR22181006-A-Phase-2-Study-to-Evaluate-the-Safety-Tolerability-and-Efficacy-of-Regimens-Containing-VIR2218-VIR3434-andor-PEGIFN-in-Subjectsnwith-Chronic-Hepatitis-B-Virus-Infection

Pegasys (pegylated interferon α -2a) - Pharma& Schweiz

tobevibart (VIR-3434) - Vir Biotech

elebsiran (VIR-2218) - Alnylam, Vir Biotech

https://euclinicaltrials.eu/ctis-public/view/2024-513177-48-00

Jun 15, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next